SG10202011017RA - Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same - Google Patents

Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Info

Publication number
SG10202011017RA
SG10202011017RA SG10202011017RA SG10202011017RA SG10202011017RA SG 10202011017R A SG10202011017R A SG 10202011017RA SG 10202011017R A SG10202011017R A SG 10202011017RA SG 10202011017R A SG10202011017R A SG 10202011017RA SG 10202011017R A SG10202011017R A SG 10202011017RA
Authority
SG
Singapore
Prior art keywords
vacciens
methods
nucleic acid
same
acid constructs
Prior art date
Application number
SG10202011017RA
Other languages
English (en)
Inventor
David Weiner
Ami Patel
Jian Yan
Original Assignee
Univ Pennsylvania
Wistar Inst
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst, Inovio Pharmaceuticals Inc filed Critical Univ Pennsylvania
Publication of SG10202011017RA publication Critical patent/SG10202011017RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10202011017RA 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same SG10202011017RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332372P 2016-05-05 2016-05-05
US201662402519P 2016-09-30 2016-09-30
US201762483979P 2017-04-11 2017-04-11

Publications (1)

Publication Number Publication Date
SG10202011017RA true SG10202011017RA (en) 2020-12-30

Family

ID=60203604

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202011017RA SG10202011017RA (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same
SG11201809780WA SG11201809780WA (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201809780WA SG11201809780WA (en) 2016-05-05 2017-05-05 Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Country Status (10)

Country Link
US (2) US11091518B2 (pt)
EP (1) EP3452068A4 (pt)
JP (2) JP7029756B2 (pt)
CN (2) CN117887735A (pt)
AU (2) AU2017261306B2 (pt)
BR (1) BR112018072719A2 (pt)
CA (1) CA3023098A1 (pt)
MX (2) MX2018013524A (pt)
SG (2) SG10202011017RA (pt)
WO (1) WO2017192947A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202011017RA (en) * 2016-05-05 2020-12-30 Univ Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same
EP3548054A4 (en) * 2016-12-02 2020-12-02 The Trustees of the University of Pennsylvania ANTI-DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST EBOLA VIRUS
CN110655572B (zh) * 2019-10-11 2022-08-16 中国科学院广州生物医药与健康研究院 一种抗丝状病毒gp蛋白的单克隆抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
KR20220012403A (ko) 2012-04-12 2022-02-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
JP6817062B2 (ja) * 2013-03-15 2021-01-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 蹄疫ウイルス（ｆｍｄｖ）コンセンサスタンパク質、そのコード配列、およびそれから作成されるワクチン
JP6462861B2 (ja) * 2014-09-03 2019-01-30 バヴァリアン ノルディック エー／エス フィロウイルス感染に対する防御免疫の誘導を目的とする方法及び組成物
WO2016054003A1 (en) * 2014-10-01 2016-04-07 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-21 as an adjuvant
SG10202011017RA (en) * 2016-05-05 2020-12-30 Univ Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same

Also Published As

Publication number Publication date
CA3023098A1 (en) 2017-11-09
AU2024203524A1 (en) 2024-06-20
US20210388033A1 (en) 2021-12-16
SG11201809780WA (en) 2018-12-28
KR20190037200A (ko) 2019-04-05
MX2018013524A (es) 2019-06-10
EP3452068A1 (en) 2019-03-13
BR112018072719A2 (pt) 2019-02-19
US20190153040A1 (en) 2019-05-23
CN110072536B (zh) 2024-02-02
CN117887735A (zh) 2024-04-16
US11091518B2 (en) 2021-08-17
WO2017192947A1 (en) 2017-11-09
JP7029756B2 (ja) 2022-03-04
AU2017261306B2 (en) 2024-02-29
CN110072536A (zh) 2019-07-30
EP3452068A4 (en) 2020-01-22
AU2017261306A1 (en) 2018-12-20
MX2023003934A (es) 2023-04-26
JP2022078067A (ja) 2022-05-24
JP2019516400A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
HK1250037A1 (zh) 抗-itga3抗體、可活化的抗-itga3抗體、及其使用方法
HK1257310A1 (zh) 抗-cd47抗體及使用方法
IL254458B (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies and methods of using them
IL270921A (en) Activatable anti-PDL1 antibodies and methods of using them
IL265598A (en) Enzymes that modify RNA-directed nucleic acids and methods for using them
IL265599A (en) RNA-directed amino acid-modifying enzymes and methods of using them
HK1250035A1 (zh) 抗cd 71抗體，可活化抗cd 71抗體及其使用方法
SG10201913767VA (en) Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
EP2836230A4 (en) ANTIGENS FILOVIRUS CONSENSUS, NUCLEIC ACID CONSTRUCTS AND VACCINES THEREOF, AND METHODS OF USE THEREOF
SG10202009182RA (en) Dna antibody constructs and method of using same
IL282233A (en) Nucleic acid structures and methods of use
PT3568475T (pt) Solução de preservação de ácido nucleico e métodos de utilização
HK1247100A1 (zh) Dna抗體構建體及其使用方法
SG11201604719WA (en) Dna antibody constructs and method of using same
EP3390442A4 (en) ANTI-C5 ANTIBODIES AND THEIR METHODS OF USE
HK1210479A1 (en) Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
IL262019A (en) Nucleic acid stabilizing reagent, kits and methods for its use
IL279272A (en) Nucleic acid constructs and methods of using them
IL268750A (en) Nucleic acid structures containing many sites for gene editing and their uses
IL273841A (en) Antibodies directed against cd137 and methods of their use
SG11202009697RA (en) Micro rna expression constructs and uses thereof
EP3347045A4 (en) ANTIBODIES GENERATED BY MVA-GH / GL-PC VACCINE NEUTRALIZING THE INFECTIOUS POWER OF HUMAN CYTOMEGALOVIRUS AND ASSOCIATED METHODS
SG10202011017RA (en) Filovirus consensus antigens, nucleic acid constructs and vacciens made therefrom, and methods of using same
PL407950A1 (pl) Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu